$35.63+0.42 (+1.21%)
News15/Ratings0
Price$35.63+1.00 (+2.90%)
01:30 PM07:30 PM
News · 26 weeks15-50%
2025-10-262026-04-19
Mix1590d
- SEC Filings6(40%)
- Insider5(33%)
- Offering1(7%)
- Leadership1(7%)
- Other1(7%)
- Earnings1(7%)
Latest news
15 items- PRChiron Real Estate Inc. Announces Dates for 2026 First Quarter Earnings Release and WebcastChiron Real Estate Inc. (NYSE:XRN) (the "Company"), announced today that it intends to release its first quarter 2026 financial results after the market closes on Wednesday, May 6, 2026. The Company intends to hold a conference call to discuss those results the following day, Thursday, May 7, 2026, at 9:00 a.m. Eastern Time. The conference call will be hosted by President and Chief Executive Officer Mark Decker, Jr., Chief Financial Officer Robert Kiernan, Chief Investment Officer Alfonzo Leon and Chief Operating Officer Danica Holley. Webcast Information Participants may access the call via live webcast by visiting the "Investor Relations" section of the Company's new website at www.ch
- SECSEC Form DEFA14A filed by Chiron Real Estate Inc.DEFA14A - Chiron Real Estate Inc. (0001533615) (Filer)
- SECSEC Form DEF 14A filed by Chiron Real Estate Inc.DEF 14A - Chiron Real Estate Inc. (0001533615) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Chiron Real Estate Inc.SCHEDULE 13G/A - Chiron Real Estate Inc. (0001533615) (Subject)
- PRAditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive OfficerBusch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most
- SECSEC Form 424B5 filed by Chiron Real Estate Inc.424B5 - Chiron Real Estate Inc. (0001533615) (Filer)
- SECSEC Form 424B5 filed by Chiron Real Estate Inc.424B5 - Chiron Real Estate Inc. (0001533615) (Filer)
- SECChiron Real Estate Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Chiron Real Estate Inc. (0001533615) (Filer)
- SECSEC Form 10-K filed by Chiron Real Estate Inc.10-K - Chiron Real Estate Inc. (0001533615) (Filer)
- INSIDERSEC Form 4 filed by General Counsel and Secretary Barber Jamie Allen4 - Chiron Real Estate Inc. (0001533615) (Issuer)
- INSIDERSEC Form 4 filed by CFO and Treasurer Kiernan Robert J4 - Chiron Real Estate Inc. (0001533615) (Issuer)
- INSIDERSEC Form 4 filed by COO Holley Danica4 - Chiron Real Estate Inc. (0001533615) (Issuer)
- INSIDERSEC Form 4 filed by CIO Leon Alfonzo4 - Chiron Real Estate Inc. (0001533615) (Issuer)
- INSIDERSEC Form 4 filed by CEO and President Decker Mark Okey Jr4 - Chiron Real Estate Inc. (0001533615) (Issuer)
- PRChiron Real Estate Inc. Announces Fourth Quarter and Full Year 2025 Financial Results–Completes Corporate Rebrand– –Announces 2026 Strategic Objectives & Full Year 2026 Core FFO Guidance– –Announces Change from Quarterly to Monthly Dividends– Chiron Real Estate Inc. (NYSE:XRN) (the "Company" or "Chiron"), today announced financial results for the three and twelve months ended December 31, 2025 and other data. Mark Decker, Jr., Chief Executive Officer and President stated, "We're about eight months into the transformation of the business and we are making great progress. I'm grateful for all the hard work that's produced these early results and the support of our Board. We can see the business we want and a path to get there. As this quarter demonstrates, we have a s